Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
13,256 total articles
Exodus Movement, Inc., a self-custodial payments and cryptocurrency platform, announced it will release its financial results for the first quarter of 2026 on May 12, 2026, after market close. The company will host an earnings webcast that day and provide supplementary materials on its website. Founded in 2015 and headquartered in Omaha, Nebraska, …
Cipher Digital reported significant progress in Q1 2026 with development milestones at its Barber Lake and Black Pearl data center campuses on schedule, signing a third AI data center lease with an investment-grade hyperscale tenant, and securing a $200 million revolving credit facility from leading global financial institutions to support ongoing …
At its General Meetings held on 5 May 2026, ArcelorMittal shareholders approved key corporate actions including a US$0.60 per share dividend distribution, re-election of current directors along with a new director, approval of share cancellation following buybacks, and renewal of board authorization to increase share capital. These approvals suppor…
Sow Good Inc. announced a $20 million non-convertible private placement credit facility with Sagol Advisors to fund its strategic acquisition of the Nachu Graphite Project in Tanzania. This funding supports Sow Good's transition into critical minerals and battery anode materials development, enhancing its position in the battery materials supply ch…
Huntington Ingalls Industries reported first quarter fiscal 2026 revenues of $3.1 billion, up 13.4% year-over-year, driven by growth across its shipbuilding and mission technology segments. Despite higher revenues, operating margins declined slightly, leading to net earnings and diluted EPS of $149 million and $3.79 respectively, unchanged from the…
Fiserv, Inc. reported first quarter 2026 GAAP revenue of $5.03 billion, down 2% year-over-year, with organic revenue down 4%. GAAP EPS declined 29%, and adjusted EPS fell 16%. The company confirmed 2026 organic revenue growth guidance of 1%-3% and adjusted EPS between $8.00 and $8.30. Operating margins declined notably compared to prior year period…
Colliers International Group Inc. announced robust first quarter 2026 financial results, with consolidated revenues rising 15% to $1.31 billion and adjusted EBITDA increasing by 8% to $124.8 million. Adjusted EPS grew 5% to $0.91, reflecting the company's diversified professional services platform's resilience amid an uneven operating environment. …
Repligen Corporation reported a robust first quarter 2026 with revenues of $194 million, up 15% year-over-year, and adjusted EPS growth of 23%. The company reiterated its full-year organic revenue growth guidance of 9%-13%, while increasing adjusted EPS guidance to $1.97-$2.05. Key strategic moves include launching a Transformation Office to enhanc…
NeurAxis, Inc., a medical technology company specializing in neuromodulation therapies, will release its first quarter 2026 financial results on May 12, 2026, prior to market open. The company will also host a conference call to discuss the results and business update. NeurAxis focuses on the commercialization of its proprietary PENFS technology, I…
Relmada Therapeutics announced presentations of two abstracts related to NDV-01, their sustained-release gemcitabine-docetaxel formulation for non-muscle invasive bladder cancer (NMIBC), at the American Urology Association 2026 event. Phase 2 data in high-risk NMIBC patients showing 9-12 month efficacy results will be presented, alongside a Phase 3…
Arvinas, a biotechnology company specializing in targeted protein degradation therapies, announced it will release its first quarter 2026 financial results on May 12, 2026, accompanied by a corporate update webcast. The company continues advancing multiple clinical-stage investigational drugs, including FDA-approved VEPPANU developed with Pfizer fo…
EVgo Inc. announced strong first quarter 2026 financial results, achieving record revenues of $110 million, a 45% increase year-over-year. The company expanded its public fast charging stalls by 25% to 5,280 and grew network throughput by 10%, reinforcing its leadership in the U.S. EV charging market. Key strategic initiatives include scaling the n…
Ocular Therapeutix announced its first quarter 2026 financial results along with significant clinical progress in its AXPAXLI program for wet age-related macular degeneration (wet AMD) and diabetic retinopathy. Key highlights include positive Phase 3 SOL-1 trial results demonstrating superiority over existing anti-VEGF treatment, initiation of the …
Eupraxia Pharmaceuticals reported encouraging EREFS (Endoscopic Reference Score) data from the ongoing Phase 1b/2a RESOLVE trial evaluating EP-104GI for eosinophilic esophagitis (EoE). The data show that a higher number of esophageal wall injections (20 injections) resulted in significant improvement in inflammation and fibrosis scores, supporting …
NRx Pharmaceuticals initiated commercial manufacturing of its preservative-free ketamine product utilizing an innovative blow-fill-seal process at a US-based facility. The product aims to address ongoing supply shortages in sterile intravenous ketamine, with production capacity supporting significant sales and scalability. This new formulation excl…
Rhythm Pharmaceuticals announced first quarter 2026 financial results featuring $60.1 million in global net product revenue for IMCIVREE, a treatment for acquired hypothalamic obesity (HO) and rare genetic obesity disorders. The company reported a successful U.S. launch post FDA approval, received European Commission authorization expanding indicat…
Fractyl Health, a clinical stage metabolic therapeutics company focused on innovative treatments for obesity and type 2 diabetes, will announce its Q1 2026 financial results and provide business updates on May 12, 2026. Additionally, CEO Dr. Harith Rajagopalan will present at the BofA Securities 2026 Health Care Conference on May 14, 2026.
Climb Bio announces significant progress in the development of budoprutug, an anti-CD19 monoclonal antibody targeting B-cell mediated immune diseases. Positive topline Phase 1 data shows robust B-cell depletion via a subcutaneous formulation, supporting advancement to patient trials. Clinical trials for primary membranous nephropathy, immune thromb…
Seres Therapeutics announced first quarter 2026 financial results showing a net loss of $19.9 million compared to net income in the prior year period, impacted by absence of payments from the 2024 VOWST sale. The company is nearing clinical data readout from an investigator-sponsored study of SER-155 for immune checkpoint inhibitor-related enteroco…
Sotera Health Company announced that Alton Shader, current CEO of Viant Medical, will become CEO and join the Board of Directors on May 26, 2026, succeeding Michael B. Petras, Jr. Petras will transition to Executive Chairman to support a smooth leadership change. Shader brings over 20 years of medical industry experience with a focus on growth and …
First Watch Restaurant Group, Inc. announced Q1 2026 financial results showing a 17.3% increase in total revenues to $331.0 million and 2.8% same-restaurant sales growth. Despite a net loss of $2.7 million, adjusted EBITDA rose to $27.8 million. The company opened 16 new restaurants and reaffirmed its full-year growth outlook while raising the low …
Shoals Technologies Group, a leading electrical infrastructure solutions provider for the energy transition market, reported Q1 2026 revenue of $140.6 million, a 74.9% increase year-over-year, driven by strong demand and market share gains. Despite a slight net loss of $0.3 million attributable to litigation settlement expenses, the company achieve…
Atea Pharmaceuticals, a clinical-stage biopharmaceutical company developing oral antiviral therapies, announced it will hold a conference call and webcast on May 12, 2026, to discuss its financial results for the first quarter ended March 31, 2026, and to provide a business update. The company is advancing its pipeline with antiviral drugs targetin…
Cellectar Biosciences announced an oversubscribed financing round totaling up to $140 million led by Nantahala Capital and other healthcare-focused investors. The funds will support the confirmatory study and NDA filing for accelerated approval of iopofosine I 131 in WaldenstrF6m macroglobulinemia with the FDA and advance their PDC delivery platfor…
Editas Medicine announced positive first quarter 2026 results including significant advancements in its lead gene editing therapy candidate EDIT-401, which demonstrated over 90% LDL cholesterol reduction in preclinical studies. The company plans to initiate a first-in-human clinical trial by the end of 2026, with early proof-of-concept data expecte…
